Kornimate/medical-research-clean huggingface dataset:
relaxation training to decrease pain and improve function in adolescents with cerebral palsy

Conditions: Cerebral Palsy

Summary: this study will examine the effectiveness of relaxation training for providing pain relief and improving physical and psychological functioning in youth with physical disabilities due to cerebral palsy.

chronic pain is a serious problem in many youths with disabilities. there is a growing body of research supporting the efficacy of relaxation training for reducing chronic pain in adults. given this evidence, there has been a growing interest in determining whether these findings also generalize to youths with chronic pain. this study will address a significant gap in the medical literature by examining the efficacy of relaxation training for providing pain relief and improving function in youths with physical disabilities. the study will evaluate the effects of relaxation training on global physiological arousal, pain-site specific muscle tension, and perceived control over pain. physiological arousal will be assessed via hand temperature and galvanic skin response. muscle tension will be assessed via surface emg biofeedback recordings before, during, and after each treatment session. self-efficacy concerning pain control will be assessed via a modified survey of pain attitudes and modified coping strategies questionnaire. sixty youth (age range 10 to 20 years old) with spastic type cerebral palsy (cp) will be randomly assigned to either the relaxation training group or a distraction control group. youths in the relaxation training group will be given eight sessions of autogenic relaxation training and will be asked to practice relaxation at home using audio tapes. youths in the distraction control group will receive eight sessions of distracting story-telling and will be asked to listen to age-appropriate audio tapes of stories at home. study visits are scheduled weekly for eight weeks. average pain intensity will be assessed with a numerical rating scale. secondary outcome measures include psychological functioning and pain interference with personal activities. medical services utilization will be assessed by asking the parent or guardian about any medications taken by the participant, any illnesses or medical complications, any medical treatments received, and the frequency of health care visits. participants will be assessed at 1, 3, 6, 9, and 12 months after treatment.

Eligibility criteria:
inclusion criteria: * cerebral palsy * referred by the study physician * chronic cerebral palsy-related pain for at least 3 months prior to study entry. the pain needs to have an average daily occurrence of 3 on a 0 to 10 scale, where 0 is no pain and 10 is extreme pain. * primary language is english exclusion criteria * acute painful conditions * cognitive impairment as determined by a score \< 12 on the modified mini-mental status exam

Keywords: relaxation training
clinical trial to assess the effectiveness of i+med's daydrop advanced ophthalmic drop

Conditions: Dry Eye Syndrome

Summary: clinical trial conducted with the aim of evaluating changes in the signs of dry eye through the change in the amount of tears produced, measured through the schirmer test. it will be performed in 45 patients diagnosed with mild/moderate dry eye who meet the inclusion/exclusion criteria. follow-up will be 12 weeks with a maximum of 4 visits.


Eligibility criteria:
inclusion criteria: * patients of both sexes over 18 years of age. * patients diagnosed with mild-moderate dry eye who meet the following characteristics: schirmer test ≥3 and ≤ 10 mm; but test ≥5 and ≤ 10 seconds and osdi ≥13 and ≤ 33. * patients without other ophthalmologic pathologies. * have ability to self-administer drops. * have ability to understand the patient information sheet. * sign the informed consent. exclusion criteria: * patients diagnosed with severe dry eye. * ingestion of parasympathomimetic or antipsychotic medications . * glaucoma. * previous cataract surgery. * systemic treatment with corticosteroids or topical treatment with any ophthalmic medication except artificial tears in the week prior to the start of study treatment. * ocular infection or clinically significant inflammation. * ocular surgery in the 3 months prior to the study. * sjögren's syndrome. * stevens-johnson syndrome. * history of allergic conjunctivitis. * pregnancy or planned lactation.

Keywords: dry eye daydrop ophtalmic tears
a study of two doses of 18f-av-45 in alzheimer's disease and healthy volunteers

Conditions: Alzheimer Disease

Summary: this study will test two different doses of florbetapir f 18 to determine which dose is best to image amyloid plaques in the brains of alzheimer's disease (ad) patients using a positron emission tomography (pet) scanner.


Eligibility criteria:
inclusion criteria (ad group): * greater than 50 years of age * probable ad according to the national institute of neurological and communication disorders and stroke-alzheimer's disease and related disorders association (nincds-adrda) criteria * mild/moderate dementia as evidenced by a mini-mental state examination (mmse) score ranging from 10 to 24, boundaries included, at screening * history of cognitive decline gradual in onset and progressive over a period of at least 6 months inclusion criteria (healthy volunteer group): * 35 to 55 years of age, inclusive * mmse of 29 or greater exclusion criteria (both groups): * neurodegenerative disorders other than ad, including, but not limited to parkinson's disease, pick's disease, fronto-temporal dementia, huntington's chorea, down syndrome, creutzfeldt-jacob disease, normal pressure hydrocephalus, and progressive supranuclear palsy * diagnosis of other dementing / neurodegenerative disease * diagnosis of mixed dementia * cognitive impairment resulting from trauma, hypoxic damage, vitamin deficiency, brain infection, brain cancer, endocrine disease, or mental retardation * clinically significant infarct or possible multi-infarct dementia as defined by the nincds criteria * evidence on screening mri or other biomarker that suggests alternate etiology for cognitive deficit (for healthy controls, evidence suggesting the presence of ad pathology) * clinically significant psychiatric disease * history of epilepsy or convulsions * clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances * current clinically significant cardiovascular disease * received investigational medication within the last 30 days

Keywords: amyloid imaging positron emission tomography 18f-av-45 florbetapir f 18 diagnostic imaging
effect of application time of 38% silver diamine fluoride solution on arresting dental caries in preschool childre

Conditions: Early Childhood Caries

Summary: to determine the optimal application time of silver diamine fluoride (38% sdf) in arresting dental caries in the primary teeth of preschool children.

methods: the randomized double blinded clinical trial will recruit 414 healthy kindergarten children aged 3-5 years old with caries and with parental consent. the sample size is sufficient for the appropriate statistical analyses. the children will receive 0.004 ml 38% sdf (typical amount applied per manufacturer's instructions) to treat each caries lesion. the children will be classified into high and low caries rates and equably allocated into nine groups of sdf application time: 3, 5, 15, 30, 45, 60, 120 and 180 seconds. the children will be followed up for 6-months in their kindergartens. clinical examinations after 6-months will be conducted to assess whether the caries is arrested. information on confounding factors, such as oral hygiene habits and the use of other fluoride agents, will be collected through a parental questionnaire at the baseline and 6-months follow-up. the examiner, the children and the children's parents will be blind to the treatment allocation. the analysis will determine the significance of differences between the means of arrested caries at the various follow-ups; and cochran-armitage test will be used to evaluate the exposure (sdf-application time) to response relationship. significance: this study will help determine the optimal application time in sdf treatment. the study provides an evidence-based protocol for the use of silver diamine fluoride to arrest tooth decay in primary teeth of young children.

Eligibility criteria:
inclusion criteria: (a) 3-5 year old children attending the first to the third year of kindergarten; (b) free from any systemic conditions and generally healthy; (c) parents sign informed consent (d) having at least 1 tooth with cavitated dentine carious lesion. exclusion criteria: * uncooperative and difficult to manage, have major systemic diseases such as porphyria, or are on long-term medication such as anti-epileptic drugs.

Keywords: silver diamine fluoride application time preschool children early childhood caries
clinical performance of a silicone hydrogel contact lens following six nights of extended wear

Conditions: Refractive Errors

Summary: the purpose of this clinical study is to evaluate the on-eye performance of an investigational soft contact lens compared to a commercially available soft contact lens following 1 week of extended wear.

subjects will be randomized to wear the investigational contact lens in 1 eye and the commercially available contact lens in the other eye. subjects will be expected to attend 3 scheduled study visits: day 1 baseline/dispense; day 2 follow-up; and week 1 follow-up/exit. the expected duration of exposure to each of the study lenses for all randomized, completed subjects was approximately 7 days / 6 nights of wear.

Eligibility criteria:
key inclusion criteria: * able to understand and sign an institutional review board/ethics committee-approved informed consent form. * successful wear of spherical soft contact lenses in both eyes during the past 3 months for a minimum of 5 days per week and in an extended wear modality a minimum of 1 night per week. * best corrected visual acuity (bcva) of 20/25 or better in each eye. * other protocol-specified inclusion criteria may apply. key exclusion criteria: * any condition, use of medications, or surgery that could contraindicate contact lens wear, as determined by the investigator. * current biofinity© lens wearer. * pregnant or breast-feeding. * other protocol-specified exclusion criteria may apply.

Keywords: contact lens extended wear overnight wear contralateral wear vision correction
investigations on improving docosahexaenoic and arachidonic acid content in preterm infant formula

Conditions: Prematurity of Fetus

Summary: the investigators examined the effect of different levels of docosahexaenoic aicd (a long chain polyunsaturated fatty acid) intake on the fatty acid composition of plasma and erythrocyte phospholipids and on the maturity of visually evoked potentials in preterm infants. as a secondary outcome the conversion of linoleic acid and alpha linolenic acid into their corresponding long chain polyunsaturated fatty acids was studied. preterm infants were randomized in a double-blind fashion to one of three formulas containing different amounts of docosahexaenoic acid during the first two weeks of postnatal life. a control group received human milk. blood samples were collected at study entry and 14 and 28 days thereafter. uniformly 13c-labeled linoleic acid and alpha linolenic acid were applied orally before blood sampling at day 28. at postconceptional ages 48 weeks and 56 weeks visually evoked potentials were recorded.


Eligibility criteria:
inclusion criteria: * preterm birth * birth weight between 1000 and 2200 g * more than 80 % of energy intake from infant formula or human milk at enrollment exclusion criteria: * apparent genetic, gastrointestinal or metabolic disorders * artificial ventilation or oxygen supply \> 30% at the time of enrollment * administration of parenteral fat emulsion (\> 1 g/kg/day for more than seven days) before or after study entry

Keywords: neurological development preterm infants fatty acid status
onq pain pump effectiveness in post operative pain control in bariatric patients

Conditions: Morbid Obesity

Summary: this study will assess the efficacy of onq pain catheters in pain reduction in the bariatric surgical population and seeks to identify if a quantifiable improved post-operative course occurs in patients receiving a catheter filled with local anesthetic versus that achieved by patients who receive a catheter filled with injectable saline.

this study will assess the efficacy of onq pain catheters in pain reduction in the bariatric surgical population. approximately 12 to 15 weight reduction surgeries are performed at william beaumont army medical center each month. it is the current practice that each patient receiving the laparoscopic gastric sleeve or laparoscopic roux-en-y gastric bypass receive an onq pain catheter during the surgery to reduce post-operative pain. there have been limited studies to quantify the efficacy of these devices. this study will seek to identify if a quantifiable improved post-operative course occurs in patients receiving a catheter filled with local anesthetic versus that achieved by patients who receive a catheter filled with injectable saline.

Eligibility criteria:
inclusion criteria: * meets criteria for bariatric surgery * consents to be in protocol * no local anesthetic allergy * will be having sleeve gastrectomy * doesn't have extensive scarring of abdominal wall that would prevent placement of onq catheter exclusion criteria: * declines to participate

Keywords: pain pump catheters bariatric surgery onq pump sleeve gastrectomy continuous infusion catheter
lung ultrasound to detect pulmonary complications in critically ill parturients

Conditions: Obstetric Complication; Lung Injury, Acute; Pulmonary Disease; Acute Respiratory Distress Syndrome

Summary: this study aims at describing the frequency, timing and type of pulmonary complications detected with lung ultrasound in critically-ill parturients in admitted to a high-dependency unit in freetown, sierra leone.

rationale: the three big 'killers' in parturients, peripartum hemorrhage, sepsis and pre-eclampsia all predispose to pulmonary complications. these complications affect management before, during and after the primary obstetric problem has been solved. a timely diagnosis and thorough follow-up of pulmonary complications may benefit parturients. lung ultrasound (lus) is a point-of-care imaging bedside tool increasingly used in the critical care setting that may prove useful in parturients. objective: to describe frequency, timing and type of pulmonary complications detected with lus in critically ill parturients in a high-dependency unit (hdu), and to determine the association with outcome. hypotheses: pulmonary complications detected by lus are frequent in parturients admitted to a hdu in a resource-limited setting, and are associated with hospital mortality. study design: a prospective observational study. study population: critically ill parturients admitted to the hdu of the princess christian maternity hospital (pcmh) in freetown, sierra leone. sample size: no formal sample size calculation is performed. based on current rates of admissions to the hdu of the pcmh the investigators expect to perform lus in at least 125 patients. methods: a trained physician performs all 12-region lus investigations. lus is performed at admission, after 24 and 48 hours, and when a patient's respiratory condition deteriorates. lus findings are reported using a standardized semi-quantitative visual lus scoring method. main study parameters/primary endpoints: the proportion of critically ill parturients admitted to the hdu of the pcmh with pulmonary complications detected by lus, including interstitial syndrome, pulmonary consolidation, and pleural effusion.

Eligibility criteria:
inclusion criteria: * admitted to the hdu of the pcmh during the study period * verbal informed consent of the patient or his/her formal representative exclusion criteria: * lung ultrasound not feasible, e.g., due to electricity breakdown, or absence of the trained sonographer.
phenotyping of primary hyperoxaluria

Conditions: Primary Hyperoxaluria

Summary: 985 / 5000 résultats de traduction primary hyperoxaluria is a rare autosomal recessive disease with an estimated prevalence of around 1 to 3 cases per million population. the most frequent attacks are urolithiasis disease and nephrocalcinosis, ultimately leading to end-stage chronic renal failure. the phenotype of this pathology is very heterogeneous, making the diagnosis difficult. there is currently a significant diagnostic delay. this is potentially due to atypical forms, or to insufficient clinicians' awareness of its research. however, the early diagnosis of this pathology is essential, since end-stage chronic renal failure can be avoided or at least delayed with early and appropriate management. the objective of the study is to describe the phenotype of currently diagnosed primary hyperoxaluria, in order to identify the classic presentations but also the characteristics of atypical presentations


Eligibility criteria:
inclusion criteria: * major or minor subject having undergone genetic research for primary hyperoxaluria between 01/01/2015 and 31/12/2019 * major subject not having expressed, after information, the reuse of his data for the purposes of this research * child and holders of parental authority who have not expressed, after information, the reuse of their data for the purposes of this research exclusion criteria: * subject (or his parental authority if he is a minor) who has expressed his opposition to participating in the study * subject not residing in france * subject of foreign nationality * subject under tutorship or curatorship * subject under safeguard of justice

Keywords: primary hyperoxaluria autosomal recessive urolithiasis. nephrocalcinosis renal failure
covid-19 primary care platform for early treatment and recovery (copper) study

Conditions: Covid19; Corona Virus Infection

Summary: the covid-19 coronavirus has led to a global pandemic of respiratory diseases with an increase in hospitalization and death risk. to keep covid-19 manageable for healthcare, early treatment is urgently needed to avoid hospitalization. dexamethasone can dampen the exaggerated cytokine response to covid-19 and is a promising agent for preventing disease aggravation, hospitalization and death. however, the evidence on the effectiveness, safety and cost-effectiveness of dexamethasone treatment in primary care is inconclusive.


Eligibility criteria:
inclusion criteria: * age ≥18 years * a positive test for sars-cov-2 * a gp consultation for deteriorating covid-19 symptoms additional inclusion criteria in order to be eligible for randomization to the trial: - exercise-induced desaturation, defined as spo2\<92% (\<90% for copd patients) and/or an absolute drop of ≥4% in spo2 after a 1-minute sit-to-stand test or - spo2\<92% (\<90% for copd patients) in rest with gp's and patient's shared decision to keep patient at home despite this in itself being an indication for referral to hospital exclusion criteria: * inability to understand and sign the written consent form * inability to perform saturation measurements or sit-to-stand test * not willing to be admitted to hospital * on the discretion of the recruiting clinician if he or she deems a patient not eligible the following criterion will be used to exclude patients from randomization to the trial: * contra-indication for dexamethasone
effects of nintendo switch on rehabilitation programs for elderly people with cognitive impairment

Conditions: Cognitive Impairment; Elderly People; Healthy Aging; Occupational Therapy

Summary: purpose: healthy aging is the process of optimizing opportunities for health, participation and safety in order to improve quality of life as people age. this study aimed to provide healthy aging for people with cognitive impairment through the use of the nintendo switch combined with occupational therapy sessions. material and methods: a randomized clinical trial was conducted. the sample was randomized using a software program, oxmar, which allowed the separation of the sample into a control group (cg), which received their usual sessions of conventional occupational therapy, and an experimental group (eg), which received therapy with nintendo switch, plus their conventional occupational therapy sessions. an 8-week intervention was conducted with nintendo switch. measures: nine hole peg test, box and block test, barthel index, whoqol-bref, csq-8.


Eligibility criteria:
inclusion criteria: * adult men or women, aged 65 years or older, cohabitating in the nursing home. * not presenting moderate or severe cognitive impairment measured through the mec- lobo test (score ≥ 24-35) (20). * agree to participate voluntarily, having read the project information sheet and signed the informed consent. exclusion criteria: * presence of neurodegenerative pathology. * presence of physical pathology that compromised the person's safety. * severe cognitive impairment.
benefits of adhd treatment in detained people

Conditions: ADHD

Summary: attention deficit hyperactivity disorder (adhd) is characterized by difficulties paying attention, poor impulse control, and hyperactive behaviors. it is associated with several health and social detrimental outcomes and leads to increased risks of criminality and recidivism. however, to date, adhd treatment has been neglected in prison. this project will test the efficacy of adhd treatment using a randomized controlled trial.

this project aims to compare the efficacy of a three-month in-prison oros-methylphenidate vs. placebo treatment on the severity of adhd core symptoms. secondary outcomes address additional important in-prison and outpatient (in-prison or post-prison) aspects: 1) reduction in acute events in prison (e.g., disciplinary sanctions, violence, misuse of adhd treatment), 2) evaluation of the risk of recidivism upon release, 3) three-month side effects of treatment, 4) in- and post-prison adherence to medication, 5) in- and post-prison study retention, 6) in- and post-prison costs-benefits of treatment, and 8) one-year rule-breaking behaviour. the outpatient part of the project will highlight long-lasting benefits of a treatment provided during three months while people are detained. these research questions will be answered using a randomized controlled trial. after randomization, the participants will undertake three months of treatment with oros-mph or placebo (1:1 ratio) while they are incarcerated. after three months, all participants will be offered the possibility to have the treatment, but they will remain blinded regarding their initial study group. all of them will benefit of a cognitive-behavioral psycho-education program during detention and a cognitive-behavioral therapy after release. the rct will provide empirical-based evidence of the benefits of in-prison adhd treatment using different perspectives: clinical, behavioral, rule-breaking-related, and economical. the investigators expect that early detection and treatment of adhd in prison will be an important public health opportunity and a cost-effective approach, likely to decrease the vulnerability of people living in detention and to promote pathways out criminal involvement.

Eligibility criteria:
inclusion criteria: * age between 18 and 65 * good command of french * stay in prison approx. 4 months at eligibility visit * endorsing clinical diagnostic criteria for dsm-5 adhd * providing written informed consent exclusion criteria: * presence of an acute uncontrolled comorbid psychiatric disorder * medical contraindication to stimulant prescription * potential adverse interaction with another medication * already receive adhd treatment

Keywords: prison health care adherence to treatment recidivism